Filtered By:
Cancer: HER2

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 260 results found since Jan 2013.

Abstract P6-08-01: A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer
In conclusion, we identified INHBA as a major regulator of metabolism and aggressiveness in HER2+ basal breast cancer cells that is associated with poor outcome in patients.Citation Format: Korkola JE, Liu M, Smith R, Liby T, Heiser L, Gray JW. A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-08-01.
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: JE Korkola, M Liu, R Smith, T Liby, L Heiser, JW Gray Tags: Poster Session Abstracts Source Type: research

Abstract P2-07-04: Treatment of metastatic breast cancer using two nanoparticles combined with siRNA targeting Twist1 to inhibit EMT
Breast cancer is the 2nd leading cause of cancer related deaths among women in the US with over 240,000 diagnoses and 40,000 deaths expected in 2014. Among the more serious and deadly forms of breast cancer are the Triple Negative Breast Cancers (TNBC) (ER-, PR-, HER2-). Mortality rates among patients rise dramatically when these cancers spread beyond the primary tumor site. Therefore reduction of tumor cell dispersion is a key component to minimizing mortality rates. Epithelial-Mesenchymal Transition (EMT) is the process by which cancer cells downregulate proteins associated with cell to cell adhesion (e.g. E-cadherin) re...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Finlay, J. B., Roberts, C. M., Lowe, G., Peng, L., Zink, J. I., Tamanoi, F., Glackin, C. A. Tags: Poster Session Abstracts Source Type: research

Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
CONCLUSION: Microbubble-liposome complex can effectively target prostate cancer cells, enabling intracellular delivery of the treatment agents with the use of ultrasound. Ultrasound and MLC-mediated delivery of survivin-targeted siRNA and doxorubicin can induce prostate cell apoptosis and block survivin expression in vitro and in vivo. PMID: 27390541 [PubMed - in process]
Source: Korean Journal of Radiology - July 10, 2016 Category: Radiology Tags: Korean J Radiol Source Type: research

Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles
Over the past decade, RNA interference (RNAi) has been ubiquitously utilized to study biological function in vitro; however, limitations were associated with its utility in vivo. More recently, small interfering RNA (siRNA) nanoparticles with improved biocompatibility have gained prevalence as a potential therapeutic option for the treatment of various diseases. The adaptability of siRNA nanoparticles enables the delivery of virtually any siRNA, which is especially advantageous for therapeutic applications in heterogeneous diseases that lack unifying molecular features, such as triple-negative breast cancer (TNBC). TNBC is...
Source: Endocrine-Related Cancer - March 9, 2017 Category: Endocrinology Authors: Parvani, J. G., Jackson, M. W. Tags: Review Source Type: research

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells
In conclusion, a combination of anti-Survivin siRNA and DOX would be a good alternative in HER2+ breast cancer therapy.PMID:36432729 | DOI:10.3390/pharmaceutics14112537
Source: Cancer Control - November 26, 2022 Category: Cancer & Oncology Authors: Sahar Eljack Emilie Allard-Vannier Yoann Misericordia Katel Herv é-Aubert Nicolas Aubrey Igor Chourpa Areeg Faggad Stephanie David Source Type: research

Abstract 3653: Nanoparticle-delivered T7-synthesized siRNA enhances cell killing in HER-2 (+) breast cancer
In this study, a modified siRNA capable of both gene silencing and immunostimulation is the payload. Here, we test the hypothesis that ligand-directed, protein-based nanoparticles delivering siRNA launch a three-pronged attack on tumors by combining missile-like targeting (known as “transductional targeting”) with siRNA-mediated gene silencing, and cytokine-mediated cell death. The latter effect will be accomplished by taking advantage of the normally undesirable cytokine-mediated cytotoxicity induced by epigenetic modifications on certain forms of siRNA, and delivering this to tumors. Here we will deliver siRNA produc...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Alonso-Valenteen, F., , M.-K. Tags: Immunology Source Type: research

Abstract 5416: Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers
Successful siRNA based therapy has the potential to revolutionize cancer therapy by mediating the silencing of any gene deemed important for disease progression. However, unprotected siRNA has a short half-life in blood and lacks the ability to selectively identify target cells. Our group is developing an effective siRNA based nanoparticle platform that overcomes these shortcomings by utilizing a mesoporous silica nanoparticle electrostatically loaded with siRNA and conjugated with an antibody for target homing. The human epidermal growth receptor type 2 (HER2) is a highly validated therapeutic target in breast cancer due ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Goodyear, S. M. Tags: Cancer Chemistry Source Type: research

The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell.
Abstract The aim of this study was to investigate the inhibitory effect of a siRNA cocktail targeting Vascular endothelial growth factor (VEGF) and Human epidermal growth factor receptor 2 (HER2) on cell proliferation, induced apoptosis and the expression of VEGF and HER2 in human gastric carcinoma cell. The silencing rate of pre-designed siRNAs that targeted VEGF and HER2 was detected by Real-time Quantitative PCR (RT-QPCR) analysis. Furthermore, the best silencing siRNA that targeted VEGF and HER2 was prepared as a cocktail to co-knockdown VEGF and HER2 expression at both mRNA and protein levels which were detec...
Source: Molecular and Cellular Biochemistry - October 26, 2013 Category: Biochemistry Authors: Liu K, Chen H, You Q, Shi H, Wang Z Tags: Mol Cell Biochem Source Type: research

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Authors: Palanca-Wessels MC, Booth GC, Convertine AJ, Lundy BB, Berguig GY, Press MF, Stayton PS, Press OW Abstract The therapeutic potential of RNA interference (RNAi) has been limited by inefficient delivery of short interfering RNA (siRNA). Tumor-specific recognition can be effectively achieved by antibodies directed against highly expressed cancer cell surface receptors. We investigated the utility of linking an internalizing streptavidin-conjugated HER2 antibody to an endosome-disruptive biotinylated polymeric nanocarrier to improve the functional cytoplasmic delivery of siRNA in breast and ovarian cancer cell...
Source: Oncotarget - February 4, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Magnetic nanocarriers for the specific delivery of siRNA: contribution of breast cancer cells active targeting for down-regulation efficiency
In conclusion, TS-MSN are promising nanocarriers for the specific and efficient delivery of siRNA to HER2-overexpressing breast cancer cells.Graphical abstract
Source: International Journal of Pharmaceutics - July 26, 2019 Category: Drugs & Pharmacology Source Type: research

Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes
Conclusions: These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.
Source: Journal of Nanobiotechnology - June 24, 2013 Category: Nanotechnology Authors: Yuya NishimuraHiroaki MiedaJun IshiiChiaki OginoToshinobu FujiwaraAkihiko Kondo Source Type: research

Abstract LB-299: Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells
Effective therapeutic strategies for in vivo siRNA delivery to knockdown genes in cells outside the liver are needed to harness RNA interference for treating cancer. EpCAM is a tumor-associated antigen highly expressed on common epithelial cancers and their tumor-initiating cells (T-IC, also known as cancer stem cells). Here we show that aptamer-siRNA chimeras (AsiC, an EpCAM aptamer linked to an siRNA sense strand and annealed to the siRNA antisense strand) are selectively taken up and knockdown gene expression in EpCAM+ cancer cells in vitro and in human cancer biopsy tissues. PLK1 EpCAM-AsiCs inhibit colony and mammosph...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Gilboa-Geffen, A., Hamar, P., Wheeler, L. A., Trifonova, R., Petrocca, F., Wittrup, A., Lieberman, J. Tags: Molecular and Cellular Biology Source Type: research

Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
Authors: Gu S, Hu Z, Ngamcherdtrakul W, Castro DJ, Morry J, Reda MM, Gray JW, Yantasee W Abstract HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on patients. We systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell ...
Source: Oncotarget - February 21, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Calcium based siRNA coating: a novel approach for knockdown of HER2 gene in MCF-7 cells using gold nanoparticles.
Authors: Sami A, Naqvi SMS, Qayyum M, Raza Rao A, Sabitaliyevich UY, Ahmad MS Abstract Surface functionalization of nanoparticles (NPs) for therapeutic siRNA delivery into cancer cells has gained interest. The present study was designed for surface functionalization of gold nanoparticles (AuNPs) for efficient siRNA delivery and knockdown in cancer cells. In order to achieve this objective, AuNPs were coated with HER2-siRNA in the presence of 11-mercaptoundecanoic acid (11-MUA), calcium chloride (CaCl2) and polyethyleneimine (PEI) in alternate charge bearing successive layers. MCF-7 cells were cultured and transfect...
Source: Cellular and Molecular Biology - October 14, 2020 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA
Sci Rep. 2022 Oct 14;12(1):17208. doi: 10.1038/s41598-022-21601-w.ABSTRACTTriple-negative breast cancer (TNBC) does not respond to HER2-targeted and hormone-based medicines. Epidermal growth factor receptor 1 (EGFR1) is commonly overexpressed in up to 70% of TNBC cases, so targeting cancer cells via this receptor could emerge as a favored modality for TNBC therapy due to its target specificity. The development of mesoporous silica nanoparticles (MSNs) as carriers for siRNAs remains a rapidly growing area of research. For this purpose, a multi-functionalized KIT-6 containing the guanidinium ionic liquid (GuIL), PEI and PEGy...
Source: Cancer Control - October 14, 2022 Category: Cancer & Oncology Authors: Javad Parnian Leila Ma'mani Mohamad Reza Bakhtiari Maliheh Safavi Source Type: research